Massachusetts Medical Device Development Center announces $200K Challenge winners
(University of Massachusetts Lowell) Entrepreneurs developing new technologies to treat blood clots, congestive heart failure, incontinence and more were the big winners at the Massachusetts Medical Device Development Center $200,000 Challenge, an annual pitch competition that showcases cutting-edge innovations in the medical-device and biotech fields. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 18, 2019 Category: International Medicine & Public Health Source Type: news

Mount Sinai researchers discover that diabetes drug may reverse heart failure
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Study finds drug could have new applications in non-diabetics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 18, 2019 Category: International Medicine & Public Health Source Type: news

Corticosteroid receptor balance regulates life and death in cardiomyocytes
Mineralocorticoid receptor (MR) antagonists are effective at treating heart failure. In this issue of Science Signaling, Oakley et al. provide new insight into their cardioprotective actions and highlight the importance of the opposing relationship between the MR and the related glucocorticoid receptor (GR) in the response to cardiomyocyte injury. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 16, 2019 Category: Science Authors: Chapman, K. E. Tags: STKE Focus Source Type: news

Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice
Stress is increasingly associated with heart dysfunction and is linked to higher mortality rates in patients with cardiometabolic disease. Glucocorticoids are primary stress hormones that regulate homeostasis through two nuclear receptors, the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), both of which are present in cardiomyocytes. To examine the specific and coordinated roles that these receptors play in mediating the direct effects of stress on the heart, we generated mice with cardiomyocyte-specific deletion of GR (cardioGRKO), MR (cardioMRKO), or both GR and MR (cardioGRMRdKO). The cardioGRKO mice ...
Source: Signal Transduction Knowledge Environment - April 16, 2019 Category: Science Authors: Oakley, R. H., Cruz-Topete, D., He, B., Foley, J. F., Myers, P. H., Xu, X., Gomez-Sanchez, C. E., Chambon, P., Willis, M. S., Cidlowski, J. A. Tags: STKE Research Articles Source Type: news

Patch Offers a New Approach for Treating Iron Deficiency
Patch-like wearables are becoming increasingly popular in medtech. The latest device to employ such a design and make medtech headlines is transdermal patch being developed by Fe3 Medical. San Antonio, TX-based Fe3 said its biphasic iontophoretic transdermal technology is for the treatment of iron deficiency anemia. The firm announced results from its first human study of the patch-like device. The human study focused on the safety and tolerability of Fe3's iontophoretic transdermal technology designed to bypass ionic resistance build up in the skin. The human study follows a series of successful preclinical studies demons...
Source: MDDI - April 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Adhesives Source Type: news

CPAP Brings Longer Life for Those With Sleep Apnea
Sleep apnea isn't just an annoyance: It's also been tied to higher risks for heart disease, heart failure and stroke. (Source: WebMD Health)
Source: WebMD Health - April 15, 2019 Category: Consumer Health News Source Type: news

Atrial Fibrillation Ablation in Heart Failure Atrial Fibrillation Ablation in Heart Failure
This review summarizes current evidence for catheter ablation in patients with atrial fibrillation and concomitant heart failure, highlighting emerging technologies and future directions.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

International Neuromodulation Society announces 14th World Congress
(International Neuromodulation Society) Researchers from 22 countries will present plenary lectures and nearly 400 abstracts top international research in neuromodulation therapies. New lines of inquiry will be presented about potentially aiding stroke recovery, heart failure, depression, paralysis, cognitive or memory issues, addiction, obesity, and anorexia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news

RV Pacing May Worsen Even Preserved-EF Heart Failure RV Pacing May Worsen Even Preserved-EF Heart Failure
A randomized clinical trial is needed, experts say, to determine whether CRT should be preferred in this setting, as is the case for reduced-EF heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

One-two punch helps solve greatest unmet need in cardiology
(UT Southwestern Medical Center) Combining a high-fat diet with a drug that raises blood pressure gave UT Southwestern researchers a 'two-hit' model, like a one-two punch to heart failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2019 Category: International Medicine & Public Health Source Type: news

Mourning the loss of a loved one increases your risk of heart disease by 64%
A study by the University of Iceland and the Karolinska Institute found people who suffer from disorders like PTSD are considerably more at risk of heart failure within the first of a traumatic event. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2019 Category: Consumer Health News Source Type: news

Medtronic touts economic data for HeartWare HVAD
Medtronic (NYSE:MDT) today touted more data on the HeartWare left-ventricular assist device it acquired in 2016, saying economic analyses of prior trials showed its cost effectiveness. The Fridley, Minn.-based medical device giant said one analysis, of data from the Lateral thoracotomy study showed that patients implanted with its HVAD pump incurred lower hospitalization and medical supply costs than patients implanted via sternotomy. The average total cost per thoracotomy patient was $204,107, compared with $260,492 for traditional median sternotomy. Lateral also showed an 87% survival rate at two years and a 30% in ...
Source: Mass Device - April 8, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Medtronic Source Type: news

Medtronic touts stroke data for HeartWare LVAD
A retrospective analysis of two studies involved the HeartWare left-ventricular assist device Medtronic (NYSE:MDT) acquired in 2016 showed that managing blood pressure reduced the severity of strokes in patients implanted with the HVAD pump. The analysis, of “destination therapy” patients who are not candidates for a heart transplant, took data from the Endurance and Endurance Supplemental studies. Results were presented this week at the annual meeting of the International Society for Heart & Lung Transplantation in London, Medtronic said. The 465-patient Endurance Supplemental study compared 308 patients i...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Abbott HeartWare International Inc. Medtronic stjudemedical Thoratec Corp. Source Type: news

U of G study reveals why heart failure patients suffer depression, impaired thinking
(University of Guelph) A new study by University of Guelph researchers explains why heart failure patients often have trouble with thinking and depression, pointing to ways to prevent and treat both heart and brain maladies through the emerging field of circadian medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2019 Category: International Medicine & Public Health Source Type: news

Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

TherOx wins FDA approval for SuperSaturated Oxygen therapy
TherOx said today that it won pre-market approval from the FDA for its SuperSaturated Oxygen Therapy system for acute myocardial infarction. Irvine, Calif.-based TherOx touted the PMA as the first heart attack treatment approved to reduce infarct size since the federal safety watchdog OK’d percutaneous coronary interventions. Indicated for patients suffering from left anterior descending ST-elevation myocardial infarction – the most deadly form of heart attack, known colloquially as the “widowmaker” – within six hours of onset and after stenting, SSO2 therapy delivers hyperbaric levels of oxyg...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Regulatory/Compliance Wall Street Beat TherOx Inc Source Type: news

Readmission Risk Up With Shorter Stay at Nursing Facility
THURSDAY, April 4, 2019 -- For patients with heart failure discharged to a skilled nursing facility (SNF) and then home, the risk for readmission is highest during the first two days at home and is attenuated with a longer SNF length of stay,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2019 Category: Pharmaceuticals Source Type: news

Older heart failure patients leave nursing facilities too early
Aging heart failure patients may be going home too early after their surgeries, a new study says. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 3, 2019 Category: Consumer Health News Source Type: news

Shorter stays in a skilled nursing facility tied to higher risk for readmission
(NYU Langone Health / NYU School of Medicine) High hospital readmission rates indicate that many elderly heart failure patients may be sent home too soon from skilled nursing facilities, a new study suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2019 Category: International Medicine & Public Health Source Type: news

Continuing ARB Recalls Shake Up Hypertension, HF Care Continuing ARB Recalls Shake Up Hypertension, HF Care
Reports of probable carcinogens found in generic sartans are causing concern in hypertension and heart failure practice, and raising larger questions about the safety of the drug supply.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 28, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Heart Failure Hospitalizations Spike When Flu Season Peaks
On average, as many as 1 in 5 heart failure hospitalizations appear to be triggered by the flu during the months when influenza viruses are circulating widely. (Source: WebMD Health)
Source: WebMD Health - March 28, 2019 Category: Consumer Health News Source Type: news

Heart Failure Hospitalizations Spike When Flu Season Peaks
Title: Heart Failure Hospitalizations Spike When Flu Season PeaksCategory: Health NewsCreated: 3/27/2019 12:00:00 AMLast Editorial Review: 3/28/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 28, 2019 Category: Cardiology Source Type: news

EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initia...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news

Flu Tied to Heart Failure Worsening
When the number of reported flu cases goes up, so does the number of hospitalizations for heart failure. (Source: NYT Health)
Source: NYT Health - March 27, 2019 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Influenza Heart Source Type: news

CardioMEMS PA-Pressure-Guided HF Therapy Safe, Reduces Events CardioMEMS PA-Pressure-Guided HF Therapy Safe, Reduces Events
Hospitalizations were fewer in a large postapproval study of heart failure management guided by the implanted pulmonary artery pressure sensor, largely consistent with the CHAMPION trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 27, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Heart Failure Hospitalizations Spike When Flu Season Peaks
WEDNESDAY, March 27, 2019 -- Weakened hearts grow weaker and fail when influenza rages throughout the land, a new study reports. Hospitalizations for heart failure increased dramatically in months when the flu season was at its worst: For every 5... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2019 Category: General Medicine Source Type: news

Adding Transition Services Does Not Aid Heart Failure Outcomes
WEDNESDAY, March 27, 2019 -- Additional transitional care services do not improve outcomes for heart failure patients discharged from the hospital, according to a study recently published in the Journal of the American Medical Association. Harriette... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 27, 2019 Category: Pharmaceuticals Source Type: news

CHF Solutions touts reduced cost, hospital stays in Aquadex Flex Flow ultrafiltation study
CHF Solutions (NSDQ:CHFS) today released results from a study of its ultrafiltration, such as with its Aquadex Flex Flow system, as compared to diuretic therapy for treating heart failure patients, touting a reduction in hospital duration and readmissions. The Eden Prairie, Minn.-based company said that results from the study were published in the Journal of Medical Economics. In the study, investigators examined clinical data from literature and hospital data from the Healthcare Cost and Utilization Project to follow decision analytic framework and explored treatment decisions, costs and outcomes for treating heart f...
Source: Mass Device - March 26, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials CHF Solutions Inc. Source Type: news

Heartmate 3 LVAD Impresses in Final MOMENTUM 3 Data Heartmate 3 LVAD Impresses in Final MOMENTUM 3 Data
Patients with advanced heart failure now have an option other than heart transplantation: a more forgiving heart pump that has now been studied out to 2 years in a large population.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 26, 2019 Category: Transplant Surgery Tags: Cardiology News Source Type: news

Scientists ID new metabolic target to prevent, treat heart failure at earliest stage
(Ohio State University Wexner Medical Center) Researchers with The Ohio State University Wexner Medical Center have identified a metabolic process in the heart that, if treated, could someday prevent or slow the progression of heart failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2019 Category: International Medicine & Public Health Source Type: news

HeartMate 3: Superior Results Hold Firm in Final Analysis (CME/CE)
(MedPage Today) -- MOMENTUM 3 data confirms better safety for newer LVAD in advanced heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 23, 2019 Category: Cardiology Source Type: news

Potentially Disruptive Medtech Company Wins FDA Nod for HF Therapy
One of the 16 promising medtech companies in the private sector, as named in a Canaccord Genuity analyst report, earlier this year, has just received approval for its heart failure therapy. Impulse Dynamics noted it nabbed a nod from FDA for the Optimizer Smart System. The Orangeburg, NY-based company’s technology delivers Cardiac Contractility Modulation (CCM). Through CGM an electrical pulse is delivered during the absolute refractory period, which is just after heart contracts. In contrast to a pacemaker or defibrillator, CCM works by modulating the strength of the heart muscle contraction rather than ...
Source: MDDI - March 23, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Bringing Home the Future of Medical Devices
There’s a massive shift taking place in U.S. healthcare, and too few device manufacturers are using it to their advantage. With health system costs ballooning more than $100 billion over the last five years while inpatient admissions remain flat1, health system executives are concluding that their inpatient-centric, treatment-centric business models are the wrong strategy. The inpatient setting is simply too expensive with too few patients utilizing it to effectively distribute the costs. This is causing profit margins to shrink at the same time as readmission penalties harm providers that fail to keep pa...
Source: MDDI - March 22, 2019 Category: Medical Devices Authors: Tom Dudnyk Tags: Business Source Type: news

Machines Treating Patients? It ’s Already Happening
Rayfield Byrd knows when it’s time to wake up every morning. The 68-year-old Oakland, Cal., resident hears a voice from the living room offering a cheery good morning. Except Byrd lives alone. A little after 8 a.m. each day, a small yellow robot named Mabu asks Byrd how he’s doing. Byrd has Type 2 diabetes and congestive heart failure, and about three years ago, he had surgery to implant a microvalve in his heart to keep his blood flowing properly. To stay healthy, he takes four medications a day and needs to exercise regularly. To make sure his heart is still pumping effectively, his doctor needs to stay on to...
Source: TIME: Health - March 21, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Artificial Intelligence Life Reinvented medicine Source Type: news

FDA Approves Optimizer Implant for CRT-Ineligible Heart Failure FDA Approves Optimizer Implant for CRT-Ineligible Heart Failure
The Impulse Dynamics pulse generator and endocardial lead system doesn't engage cardiac rhythm but is said to remodel heart muscle and function with long-term use, making pumping more efficient.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 21, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves New Device for Chronic, Moderate-to-Severe Heart Failure
THURSDAY, March 21, 2019 -- The Optimizer Smart system was approved for treatment of patients with chronic, moderate-to-severe heart failure who are not eligible for treatment with other heart failure devices, including cardiac resynchronization... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Otimizer Smart heart failure device from Impulse Dynamics
The FDA today said it approved the Optimizer Smart heart failure device developed by Impulse Dynamics under its breakthrough device designation. The Stuttgart, Germany-based company’s device is designed to remodel the myocardium to increase the heart’s efficiency using “cardiac contractility modulation” – non-excitatory electrical pulses delivered to the heart muscle. An FDA advisory panel last December recommended approval for Optimizer Smart, voting voted 12-1 on safety, 11-2 on efficacy and 12-0, with a single abstention, that its benefits outweigh the risks. The system has had CE Mark appr...
Source: Mass Device - March 21, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Impulse Dynamics Source Type: news

The toilet seat that could save millions of lives by detecting heart failure
Scientists from the Rochester Institute of Technology in New York have created a gadget which has sensors in to detect someone's blood pressure and heart rate while they're on the loo. (Source: the Mail online | Health)
Source: the Mail online | Health - March 21, 2019 Category: Consumer Health News Source Type: news

FDA approves new device for treating moderate to severe chronic heart failure in patients
Device to treat heart failure was given Breakthrough Device designation because it treats a life-threatening disease and addresses unmet clinical need. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2019 Category: American Health Source Type: news

New Heart Failure Device Is Approved
THURSDAY, March 21, 2019 -- The Optimizer Smart System has been approved by the U.S. Food and Drug Administration for people with chronic, moderate-to-severe heart failure who are not candidates for other heart failure remedies. " Patients with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 21, 2019 Category: General Medicine Source Type: news

Trastuzumab Tied to Higher Long - Term Risk for Heart Failure
Increased risk for heart failure seen in breast cancer survivors given trastuzumab rather than chemo alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 21, 2019 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Trastuzumab Tied to Higher Long-Term Risk for Heart Failure
WEDNESDAY, March 20, 2019 -- Compared with chemotherapy alone, trastuzumab is associated with a twofold increased long-term risk for heart failure in breast cancer survivors, according to a study published in the March 1 issue of JACC: Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news

Bet Your Toilet Seat Can & #039;t Do This!
Every now and then we come across a technology that just begs the question: How on Earth did they think of that? Case in point, a toilet seat designed to detect heart failure by measuring a patient's biometrics during "natural" processes.  A team of researchers at Rochester Institute of Technology (RIT) are responsible for the idea, which is intended to lower hospital readmission rates by alerting doctors of a patient's deteriorating cardiovascular condition before the patients even realize they have symptoms. The idea is for hospitals to buy the seats and issue them to heart failure patie...
Source: MDDI - March 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Low EF Heart Failure Benefits Most From SGLT2 Diabetes Drug
(MedPage Today) -- DECLARE substudy doesn't leave HFpEF entirely out, though (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 20, 2019 Category: Cardiology Source Type: news

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial...
Source: Amgen News Release - March 20, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

A Better Cardiac Pump for People With Heart Failure?
Title: A Better Cardiac Pump for People With Heart Failure?Category: Health NewsCreated: 3/19/2019 12:00:00 AMLast Editorial Review: 3/20/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 20, 2019 Category: Cardiology Source Type: news

Toilet seat that detects congestive heart failure getting ready to begin commercialization
(Rochester Institute of Technology) A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers aims to lower the hospital readmission rates of patients with congestive heart failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

Echocardiography identifies patients for valve repair
Echocardiography can help determine which patients with heart failure and leaking...Read more on AuntMinnie.comRelated Reading: Lung ultrasound beats chest x-ray for heart failure detection Societies renew call to pull ultrasound contrast warning ACC, ASE release echocardiography training guidance ASE offers TEE guidelines for congenital heart disease Heart valve-tracking algorithm boosts viability of 4D MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 19, 2019 Category: Radiology Source Type: news

A Better Cardiac Pump for People With Heart Failure?
TUESDAY, March 19, 2019 -- A new version of an implantable heart pump could cut the risk of blood clots, bleeding and stroke in patients with advanced heart failure, according to a study funded by the device's maker. The study included more than a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 19, 2019 Category: General Medicine Source Type: news

Blocking a pathway to heart failure
Researchers identified drugs to restore heart muscle function in rodents with heart failure. The findings may help pave the way for a similar approach in people. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - March 19, 2019 Category: Consumer Health News Source Type: news